Abstract
Menin is a tumour suppressor protein whose loss or inactivation causes multiple endocrine neoplasia 1 (MEN1), a hereditary autosomal dominant tumour syndrome that is characterized by tumorigenesis in multiple endocrine organs1. Menin interacts with many proteins and is involved in a variety of cellular processes2,3,4,5,6,7,8. Menin binds the JUN family transcription factor JUND and inhibits its transcriptional activity2,9. Several MEN1 missense mutations disrupt the menin–JUND interaction, suggesting a correlation between the tumour-suppressor function of menin and its suppression of JUND-activated transcription2,10. Menin also interacts with mixed lineage leukaemia protein 1 (MLL1), a histone H3 lysine 4 methyltransferase, and functions as an oncogenic cofactor to upregulate gene transcription and promote MLL1-fusion-protein-induced leukaemogenesis5,7,11,12. A recent report on the tethering of MLL1 to chromatin binding factor lens epithelium-derived growth factor (LEDGF) by menin indicates that menin is a molecular adaptor coordinating the functions of multiple proteins13. Despite its importance, how menin interacts with many distinct partners and regulates their functions remains poorly understood. Here we present the crystal structures of human menin in its free form and in complexes with MLL1 or with JUND, or with an MLL1–LEDGF heterodimer. These structures show that menin contains a deep pocket that binds short peptides of MLL1 or JUND in the same manner, but that it can have opposite effects on transcription. The menin–JUND interaction blocks JUN N-terminal kinase (JNK)-mediated JUND phosphorylation and suppresses JUND-induced transcription. In contrast, menin promotes gene transcription by binding the transcription activator MLL1 through the peptide pocket while still interacting with the chromatin-anchoring protein LEDGF at a distinct surface formed by both menin and MLL1.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity
Epigenetics & Chromatin Open Access 09 August 2022
-
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer
Breast Cancer Research Open Access 18 July 2022
-
Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation
BMC Endocrine Disorders Open Access 14 March 2022
Access options
Subscribe to Journal
Get full journal access for 1 year
$199.00
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.




References
Chandrasekharappa, S. C. et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404–407 (1997)
Agarwal, S. K. et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96, 143–152 (1999)
Busygina, V., Kottemann, M. C., Scott, K. L., Plon, S. E. & Bale, A. E. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res. 66, 8397–8403 (2006)
Chen, G. et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol. Cancer Res. 6, 1894–1907 (2008)
Hughes, C. M. et al. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol. Cell 13, 587–597 (2004)
Jin, S. et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63, 4204–4210 (2003)
Yokoyama, A. et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 24, 5639–5649 (2004)
Yang, Y. & Hua, X. In search of tumor suppressing functions of menin. Mol. Cell. Endocrinol. 265–266, 34–41 (2007)
Knapp, J. I. et al. Identification and characterization of JunD missense mutants that lack menin binding. Oncogene 19, 4706–4712 (2000)
Groussin, L. & Bertherat, J. Mechanisms of multiple endocrine neoplasia type 1: evidence for regulation of the AP-1 family of transcription factors by menin. Eur. J. Endocrinol. 141, 15–16 (1999)
Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev. Cancer 7, 823–833 (2007)
Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207–218 (2005)
Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36–46 (2008)
Caslini, C. et al. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67, 7275–7283 (2007)
Grembecka, J., Belcher, A. M., Hartley, T. & Cierpicki, T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J. Biol. Chem. 285, 40690–40698 (2010)
Murai, M. J., Chruszcz, M., Reddy, G., Grembecka, J. & Cierpicki, T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem. 286, 31742–31748 (2011)
Lamb, J. R., Tugendreich, S. & Hieter, P. Tetratrico peptide repeat interactions: to TPR or not to TPR? Trends Biochem. Sci. 20, 257–259 (1995)
Llano, M., Morrison, J. & Poeschla, E. M. Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Curr. Top. Microbiol. Immunol. 339, 125–146 (2009)
Gallo, A. et al. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 21, 6434–6445 (2002)
Yang, S. H., Whitmarsh, A. J., Davis, R. J. & Sharrocks, A. D. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 17, 1740–1749 (1998)
Yazgan, O. & Pfarr, C. M. Regulation of two JunD isoforms by Jun N-terminal kinases. J. Biol. Chem. 277, 29710–29718 (2002)
Mensah-Osman, E. J., Veniaminova, N. A. & Merchant, J. L. Menin and JunD regulate gastrin gene expression through proximal DNA elements. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G783–G790 (2011)
Otwinowski, Z. & Minor, W. in Methods in Enzymology Vol. 26 (eds Carter, C. W. Jr & Sweet, R. M.) 307–326 (Academic Press, 1997)
de La Fortelle, E. & Bricogne, G. Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. Methods Enzymol. 276, 472–494 (1997)
Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–119 (1991)
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010)
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007)
Acknowledgements
We thank G. Wilding for the human JUND complementary DNA and P. Cherepanov for the human LEDGF cDNA. We thank Y. Chen and W. Deng for help at various stages of the project. M.L. is a Howard Hughes Medical Institute Early Career Scientist. Work was supported by National Institutes of Health grants (GM 083015-01 to M.L., R01-DK085121 to X.H. and R37-DK45729 to J.L.M.), an American Cancer Society Research Scholar grant (to M.L.) and an American Association for Cancer Research Caring for Carcinoid Foundation Grant (to X.H.). The General Medicine and Cancer Institutes Collaborative Access Team has been funded in whole or in part with federal funds from the National Cancer Institute (grant Y1-CO-1020) and the National Institute of General Medical Science (grant Y1-GM-1104). Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract number DE-AC02-06CH11357.
Author information
Authors and Affiliations
Contributions
J.H. is responsible for the bulk of the experiments, B.G. for the qRT-PCR and ChIP assays; B.W. for the co-immunoprecipitation and in vivo phosphorylation analyses, S.M. for the luciferase assay, N.A.V. and J.L.M. for the analysis of gastrin expression, and K.W. for some of the protein purification. M.L. and X.H. supervised the project and wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-19 with legends, Supplementary Tables 1-6, Supplementary Text, a Supplementary Discussions and additional references. (PDF 2464 kb)
Rights and permissions
About this article
Cite this article
Huang, J., Gurung, B., Wan, B. et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482, 542–546 (2012). https://doi.org/10.1038/nature10806
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature10806
This article is cited by
-
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes
Nature Cell Biology (2023)
-
Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation
BMC Endocrine Disorders (2022)
-
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer
Breast Cancer Research (2022)
-
Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity
Epigenetics & Chromatin (2022)
-
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
Nature Cancer (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.